News LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Real-time Estimate Cboe BZX Other stock markets 02:53:17 2024-05-09 pm EDT			5-day change	1st Jan Change
6.905 ^USD	-1.07%		+7.12%	-10.66%

12:34pm	LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated	MT
12:17pm	LifeStance Health Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LifeStance Health Q1 Loss Narrows as Revenue Increases; 2024 Revenue Outlook Reiterated	06:34am	MT
LifeStance Health Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06:17am	CI
LifeStance Health Group, Inc. Announces Resignation of Danish Qureshi as President and Chief Operating Officer, Effective June 30, 2024	06:17am	CI
Earnings Flash (LFST) LIFESTANCE HEALTH Posts Q1 Revenue $300.4M, vs. Street Est of $299M	06:15am	MT
LifeStance Health: Q1 Earnings Snapshot	06:10am	AQ
LifeStance Reports First Quarter 2024 Results	06:00am	GL
LifeStance Health Group, Inc. Provides Earnings Guidance for the Second Quarter of 2024; Reiterates Earnings Guidance for the Full Year of 2024	06:00am	CI
LifeStance Destigmatizes Mental Health in Newest "Not One Face" Campaign Featuring Photography from Leica Ambassadors	May. 01	PR
LifeStance to Host First Quarter 2024 Earnings Conference Call on May 9, 2024	Apr. 18	GL
LifeStance Appoints Dr. Teresa DeLuca to Board of Directors	Mar. 12	PR
LifeStance Health Appoints Teresa DeLuca to Its Board of Directors	Mar. 12	CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST	Mar. 11	PR
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	Mar. 06	MT
Lifestance Health Group Insider Sold Shares Worth $923,391, According to a Recent SEC Filing	Mar. 05	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating	Mar. 04	MT
Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST	Mar. 03	PR
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating	Feb. 29	MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating	Feb. 29	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 28	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Feb. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Summary

Filters